A decade's evidence review of sildenafil citrate.
- Author:
Kai ZHANG
1
;
Ji-Chuan ZHU
Author Information
1. Department of Urology, The First Hospital of Peking University, Beijing 100034, China.
- Publication Type:Journal Article
- MeSH:
Erectile Dysfunction;
drug therapy;
Evidence-Based Medicine;
Humans;
Male;
Phosphodiesterase Inhibitors;
adverse effects;
therapeutic use;
Piperazines;
adverse effects;
therapeutic use;
Purines;
adverse effects;
therapeutic use;
Retrospective Studies;
Sildenafil Citrate;
Sulfones;
adverse effects;
therapeutic use
- From:
National Journal of Andrology
2009;15(1):3-6
- CountryChina
- Language:Chinese
-
Abstract:
Erectile dysfunction (ED) is one of the most popular and disturbing sexual problems, which impairs patients' health and affects their quality of life. Sildenafil citrate, the first oral PDE-5 inhibitor in the world, has established its efficacy and safety credit in both doctors and ED patients. The authors reviewed the results of related studies in the last decade and made deeper insights into the use of sildenafil citrate in such aspects as the general drug tolerance and its influence on the cardiovascular system, potentiality of concomitant diseases with co-administration of other drugs, long-term safety, and ocular and genital safety.
